PERCOCET oxycodone hydrochloride and acetaminophen
Refer to the “Also Known As” section to reference different products that include the same medication as PERCOCET.
Drug Basics
Brand Name: PERCOCET
Generic Name: OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN
Drug Type: HUMAN PRESCRIPTION DRUG
Route: ORAL
Dosage Form: TABLET
Packager: Endo Pharmaceuticals Inc.
Data Current As Of: 2021-02-11
WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME, CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY, and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Addiction, Abuse, and Misuse
PERCOCET exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing PERCOCET, and monitor all patients regularly for the development of these behaviors and conditions [see WARNINGS].
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS):
To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products [ see WARNINGS] . Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to
-
complete a REMS-compliant education program,
-
counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products,
-
emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and
-
consider other tools to improve patient, household, and community safety.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of PERCOCET. Monitor for respiratory depression, especially during initiation of PERCOCET or following a dose increase [see WARNINGS].
Accidental Ingestion
Accidental ingestion of PERCOCET, especially by children, can result in a fatal overdose of PERCOCET [see WARNINGS].
Neonatal Opioid Withdrawal Syndrome
Prolonged use of PERCOCET during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see WARNINGS].
Cytochrome P450 3A4 Interaction
The concomitant use of PERCOCET with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving PERCOCET and any CYP3A4 inhibitor or inducer [see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS; Drug Interactions].
Hepatotoxicity
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death [see WARNINGS, PRECAUTIONS; Drug Interactions].
-
Reserve concomitant prescribing of PERCOCET and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
-
Limit dosages and durations to the minimum required.
-
Follow patients for signs and symptoms of respiratory depression and sedation.
Indications & Usage
PERCOCET is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Limitations of Use
Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve PERCOCET for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]
- Have not been tolerated, or are not expected to be tolerated,
- Have not provided adequate analgesia, or are not expected to provide adequate analgesia
Contraindications
PERCOCET is contraindicated in patients with:
- Significant respiratory depression [see WARNINGS ]
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see WARNINGS ]
- Known or suspected gastrointestinal obstruction, including paralytic ileus [see WARNINGS ]
- Hypersensitivity to oxycodone, acetaminophen, or any other component of the product (e.g., anaphylaxis) [see WARNINGS, ADVERSE REACTIONS ]
Medication Guide PERCOCET® (ˈpər-kō-ˌset) Tablets, CII |
|
PERCOCET is:
|
|
Important information about PERCOCET tablets:
|
|
Do not take PERCOCET if you have:
|
|
Before taking PERCOCET , tell your healthcare provider if you have a history of:
Tell your healthcare provider if you are:
|
|
When taking PERCOCET:
|
|
While taking PERCOCET DO NOT:
|
|
The possible side effects of PERCOCET:
Get emergency medical help or call 911 right away if you have:
These are not all the possible side effects of PERCOCET. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov. Distributed by: Endo Pharmaceuticals Inc. Malvern, PA 19355 1-800-462-3636 Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 |
|
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 08/2020 |
also known as
- ENDOCET (tablet)
- Nalocet (tablet)
- Oxycodone and Acetaminophen (tablet)
- OXYCODONE AND ACETAMINOPHEN (solution)
- OXYCODONE APAP (tablet)
- oxycodone hydrochloride and acetaminophen (solution)
- Oxycodone Hydrochloride and Acetaminophen (tablet)
- Oxycodone/APAP (tablet)
- Primlev (tablet)
- Prolate (tablet)
- Prolate (solution)
- Xartemis XR (tablet, coated)
Or Browse by Name
At Healthgrades, our Editorial Team works hard to develop complete, objective and meaningful health information to help people choose the right doctor, right hospital and right care. Our writers include physicians, pharmacists, and registered nurses with firsthand clinical experience. All condition, treatment and wellness content is medically reviewed by at least one medical professional ensuring the most accurate information possible. Learn more about our editorial process.